

2016 Future Horizons and Growth Strategies in the French Nucleic Acid Testing Market: Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

<https://marketpublishers.com/r/201C61873AEEN.html>

Date: November 2015

Pages: 1125

Price: US\$ 5,360.00 (Single User License)

ID: 201C61873AEEN

Abstracts

Highlights

Comprehensive 1,125-page market segmentation analysis of the French NAT market.

Major issues pertaining to the French NAT laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.

An extensive review of DNA probe and biochip technologies, test formats, detection methodologies, trends in testing automation and amplification methods.

Five-year test volume and reagent sales forecasts for the following categories:

Infectious Diseases

Cancer

Forensic Testing

Genetic Diseases

Paternity Testing/HLA Typing

Review of testing methodologies and instrumentation technologies.

Feature comparison of automated and semiautomated analyzers.

Sales and market shares of leading suppliers.

Over 60 specific opportunities for NAT instruments, test systems, IT and auxiliary products.

Profiles of major suppliers, and emerging market entrants, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Business planning issues and concerns.

Contains 1, 125 pages and 58 tables

Contents

I. INTRODUCTION

II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Instrumentation
- B. Reagent Kits and Test Systems/panels
- C. Computers, Software and Automation
- D. Auxiliary Products

III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

IV. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies For Decentralized Testing Markets

V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge And Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VI. WORLDWIDE MARKET AND TECHNOLOGY REVIEW

- A. DNA Sequencing
 - 1. Introduction
 - 2. Sequencing Methods
 - 3. Autoradiography
 - 4. The Human Genome Project
 - 5. Sequencing Automation
 - 6. Image Scanners

7. Fluorescent Detection
8. Gene Profiling
9. Gene Expression
10. Polymorphism Screening
11. Protein Interaction Networks
- B. DNA and RNA Probe Technologies
 1. Basic Principles
 2. Probe Preparation
 3. The DNA Probe Test
 4. Test Formats
 5. Labeling Techniques
 6. Amplification Methods
- C. Detection Technologies
 1. Radioactive Methods
 - a. Overview
 - b. Major Isotopes
 - P-32
 - S-35
 - H-3
 - I-125
 2. Non-Isotopic Methods
 - a. Enzymatic Labels
 - b. Chemical Labeling
 - Indirect Chemical Labeling
 - Direct Chemical Labeling
 - c. Fluorescence
 - d. Chemiluminescence
 - e. Electrical Conductivity
- D. Molecular Diagnostic Instrumentation Review
 1. Abbott LCx
 2. Beckman Coulter/Biomek FK
 3. BD Viper System with XTR Technology
 4. BD Innova
 5. Becton Dickinson SDA
 6. bioMerieux NucliSENS easyMAG
 7. bioMerieux NucliSENS easyQ and MiniMAG
 8. Bio-Rad GeneScope
 9. Cepheid GeneXpert
 10. Curetis Unyvero

11. GenMark Dx eSensor XT-8
12. Hologic/Gen-Probe Panther
13. Hologic/Gen-Probe Tigris/DTS
14. HTG Molecular Edge
15. Life Technologies QuantStudio Dx
16. Qiagen QIASymphony RGQ
17. Roche Cobas Amplicor
18. Roche Cobas TaqMan
19. Roche Cobas TaqMan
20. Roche Cobas TaqMan AmpliPrep
21. Roche LighCycler
22. Roche Cobas 4800
23. Roche Cobas s
24. Siemens Versant
25. Tecan LS Series

E. Biochips: Genosensors, Microarrays, and Labs-on-the-Chip

Liquid Transportation and Mixing

Separation

Reaction

Detection

F. Pharmacogenomics

G. Major Applications

1. Microbiology/Infectious Diseases

a. Overview

b. Major Infectious Diseases

AIDS: HIV/HIV-1/2/Combo, HIVAg/HIV NAT, Western Blot, HTLV-I/II

Adenovirus

Aeromonas

Anthrax/Bacillus Anthracis

Arboviruses

Babesiosis

Bacillary Epithelioid Angiomatosis (BEA) and Other Bartonella (Rochalimaea)

Blastocystis Hominis

Brucella

Campylobacter

Candida

Chagas Disease

Chancroid

Chlamydia

Clostridium Difficile
Coronaviruses
Coxsackieviruses
Creutzfeldt-Jakob's Disease
Cryptosporidium Parvum
Cyclospora Cayetanensis
Cytomegalovirus
Ebola Virus
E. Coli
EchoVirus
Encephalitis
Enteroviruses
Epstein-Barr Virus
Giardia Lamblia
Gonorrhea
Granuloma Inguinale
Hantavirus
Helicobacter Pylori
Hepatitis: HAV NAT, HBV NAT, HBs Ag, HCV, HCV NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, ALT/SGPT
Herpes Simplex Virus
Human Herpes Virus-6 (HHV-6)
Influenza Viruses
Legionella
Lyme Disease
Lymphogranuloma Venereum (LGV)
Malaria
Measles (Rubeola)
Meningitis
Microsporidium
Mononucleosis
Mumps
Mycoplasma
Papillomaviruses
Parvovirus B19
Pneumonia
Polyomaviruses
Pseudomonas Aeruginosa
Rabies

Respiratory Syncytial Virus (RSV)

Rhinoviruses

Rotavirus

Rubella

Salmonellosis

Septicemia

Shigellosis

Staphylococcus Aureus

Streptococci

Syphilis

Toxoplasmosis

Trichomonas Vaginalis

Tuberculosis

Vibrio

West Nile Virus

Yersina

2. Cancer Testing

a. Overview

b. Major Cancer Types

Prostate

Lung

Colon and Rectum

Breast

Skin

Uterine

Leukemia

Oral

c. Oncogenes

Abl/abl-bcr

AIB1

BCL-2

BRCA1

CD44

C-fos

C-myb

C-myc

CYP17

Erb-B

HPC1

N-myc

P40

P51

P53

PIK3CA

PTI-1

Ras

Reg

Sis

Src

3. Genetic Diseases

a. Overview

b. Nucleic Acid Amplification

c. Chromosome Imaging

d. Genomics Technologies

e. Proteomics Technologies

f. Current Pharmacogenomic Tests

g. Future Pharmacogenomic Testing

h. Major Diseases

Achondroplasia

Autosomal Dominant Polycystic Kidney Disease

Cancer

Cosmetogenomics

Cystic Fibrosis

Down's Syndrome

Duchenne and Becker Muscular Dystrophy

Factor V (Leiden)

Factor IX Deficiency

Fragile X Syndrome

Heart Disease

Hemochromatosis

Hemophilia

Huntington's Disease

Maternal-Fetal Incompatibility

Multiple Endocrine Neoplasia

Phenylketonuria (PKU)

Polycystic Kidney Disease (PKD)

Prenatal Screening

Retinitis Pigmentosa

- Retinoblastoma
- Sickle Cell Anemia
- Spinal Muscular Atrophy
- Vitamin B12 Metabolism
- i. Social Issues and Concerns
- 4. Forensic Testing
 - a. Overview
 - b. Multilocus and Single Locus Probes
 - Multilocus Probes
 - Single Locus Probes
 - PCR and RFLP
 - c. The FBI
 - d. DNA Profile Data Banks
 - U.S.A.
 - U.K.
 - e. Judicial Implementation
 - f. Major Crime Categories
 - g. Factors Contributing to the DNA Probe Market Expansion
 - Technology Availability
 - Use of Hair as Evidence
 - h. Wildlife Forensics
- 5. Paternity Testing/HLA Typing
- 6. Other Applications
 - a. Disease Susceptibility Testing
 - b. Cardiovascular Diseases
 - c. Diabetes
 - d. Alzheimer's Disease
 - e. Periodontal Disease
 - f. Plasma Purification
 - g. Organ Transplantation
 - h. Water Contamination
 - i. Other
- H. Competing/complementing
 - 1. Monoclonal Antibodies/Immunoassays
 - 2. RNA Probes
 - 3. Two-Dimensional Electrophoresis
 - 4. Flow Cytometry

VII. FRANCE MOLECULAR DIAGNOSTICS MARKET

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Test Volume and Sales Forecasts, Major Supplier Sales and Market Shares

VIII. COMPETITIVE ASSESSMENTS

Abbott
Affymetrix
Agilent Technologies
Applied Gene Technologies
Arca Biopharma
Beckman Coulter/Danaher
Becton Dickinson
Biokit
BioMerieux
Bio-Rad
Biotest
Cepheid
CellMark Forensics/LabCorp
Decode Genetics
Diadexus
Eiken
Elitech Group
Enzo
Exact Sciences
Fujirebio
Grifols
Hologic/Gen-Probe
Illumina
Kreatech/Leica
Li-Cor Biosciences
Monogram Biosciences/LabCorp
Myriad Genetics
Ortho-Clinical Diagnostics
Perkin Elmer/Caliper
Proteome Sciences

Qiagen
Roche
Scienion
Sequenom
Shimadzu
Siemens
Sierra Molecular
Takara Bio
Tecan Group
Thermo Fisher

XIII. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING MOLECULAR DIAGNOSTIC TECHNOLOGIES

List Of Tables

LIST OF TABLES

Major Companies Developing or Marketing AIDS Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Adenovirus Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Bartonella Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Campylobacter Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Candida Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Chlamydia Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Clostridium Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Coronavirus Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Cryptosporidium Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing CMV Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Echovirus Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Enterovirus Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing EBV Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Giardia Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Gonorrhea Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Hantavirus Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Helicobacter Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Hepatitis Molecular Diagnostic and Other

Direct Identification Tests

Major Companies Developing or Marketing Herpes Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Influenza Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Legionella Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Lyme Disease Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Measles Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Meningitis Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Mononucleosis Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Mumps Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Mycoplasma Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Pneumonia Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing RSV Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Rotavirus Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Rubella Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Salmonella Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Septicemia Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Shigella Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Streptococci Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Syphilis Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Toxoplasmosis Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Trichomonas Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Tuberculosis Molecular Diagnostic and Other Direct Identification Tests

Oncogenes Potential Application in Cancer Diagnosis

Major Companies Developing or Marketing Cancer Molecular Diagnostic Tests

Major Companies Developing or Marketing Molecular Diagnostic Tests For Genetic Diseases

France Molecular Diagnostics Test Volume And Sales By Major Application 2014-2019

France Laboratories Performing DNA Sequencing By Market Segment 2014

France Molecular Diagnostics Market Potential Laboratory Universe by Market Segment 2014

France Molecular Diagnostics Test Volume By Major Application 2014-2019

France Major Infectious Disease Test Volume by Assay 2014-2019

France Major Infectious Disease Test Volume by Method 2014

France Molecular Diagnostics Market By Major Application 2014-2019

France Molecular Diagnostics Market Estimated Sales And Market Shares of Major Suppliers 2014

France Major Infectious Disease Diagnostics Market by Assay 2014-2019

France AIDS Testing Market Estimated Sales by Major Supplier 2014

France Adenovirus Testing Market Estimated Sales by Major Supplier

France Chlamydia Testing Market Estimated Sales by Major Supplier

France CMV Testing Market Estimated Sales by Major Supplier

France Gonorrhea Testing Market Estimated Sales by Major Supplier

France Hepatitis Testing Market Estimated Sales by Major Supplier

France Hepatitis C Testing Market Estimated Sales by Major Supplier

France HIV/Hepatitis Blood Screening NAT Market Reagent Sales by Major Supplier

France Herpes Testing Market Estimated Sales by Major Supplier

France Influenza Testing Market Estimated Sales by Major Supplier

France Meningitis Testing Market Estimated Sales by Major Supplier

France Mycoplasma Testing Market Estimated Sales by Major Supplier

France RSV Testing Market Estimated Sales by Major Supplier

France Shigella Testing Market Estimated Sales by Major Supplier

I would like to order

Product name: 2016 Future Horizons and Growth Strategies in the French Nucleic Acid Testing Market: Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Product link: <https://marketpublishers.com/r/201C61873AEEN.html>

Price: US\$ 5,360.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/201C61873AEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970